Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma

BACKGROUND: Nivolumab is approved for patients with metastatic renal cell carcinoma (mRCC) refractory to prior antiangiogenic therapy. The clinical activity of nivolumab in patients with non-clear cell RCC subtypes remains unknown as these patients were excluded from the original nivolumab trials. M...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Immunother Cancer
Autori principali: Koshkin, Vadim S., Barata, Pedro C., Zhang, Tian, George, Daniel J., Atkins, Michael B., Kelly, William J., Vogelzang, Nicholas J., Pal, Sumanta K., Hsu, JoAnn, Appleman, Leonard J., Ornstein, Moshe C., Gilligan, Timothy, Grivas, Petros, Garcia, Jorge A., Rini, Brian I.
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2018
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5789686/
https://ncbi.nlm.nih.gov/pubmed/29378660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0319-9
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi